The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has brought significant challenges to all healthcare providers in the United States. Hospital pharmacy departments are being forced to swiftly implement new working conditions that impact frontline clinical pharmacists. Some of the strategies being implemented for clinical pharmacist staffing include remote work from home, telepharmacy coverage, cross-training of clinical pharmacists to cover new patient care units, and pharmacist reassignment to other pharmacies across the institution. As the pandemic continues---and will likely continue for the near future---clinical pharmacists must do their best to adapt to the rapid and daily disruptions in pharmacy practice.

Emergency medicine pharmacists (EMPs) take pride in their ability to adapt to constantly changing situations while caring for critically ill patients in the emergency department (ED) setting. The ability to adapt has taken on a new meaning during the coronavirus disease 2019 (COVID-19) pandemic. While EDs in some cities (eg, New York City, Detroit) have been overwhelmed with critically ill patients with COVID-19, other EDs are experiencing low census, especially of critically ill patients. While low ED census may be a welcome relief for most EDs, which have been struggling with overcrowding, it also allows for EMPs to pursue new opportunities to be involved in caring for critically ill patients in other areas of the hospital. With ample evidence supporting clinical pharmacist participation on cardiopulmonary resuscitation (ie, code blue) and rapid response teams (RRTs) to optimize medication selection and dosing while improving patient outcomes, participating in a multidisciplinary team responsible for airway management of patients with COVID-19 could serve as a new avenue to improve patient outcomes.^[@CIT0001]^

"COVID-19 airway teams" and "COVID-19 rapid sequence intubation (RSI) teams" are being implemented by institutions across the United States to decrease healthcare worker exposure to SARS-CoV-2 and to conserve personal protective equipment (PPE). A COVID-19 airway team is responsible for doing all endotracheal intubations of SARS-CoV-2--positive patients or patients under investigation for suspected COVID-19 throughout the hospital, including intensive care units (ICUs) and the ED. COVID-19 airway teams typically consist of an anesthesiologist or emergency medicine physician, a senior medical resident (at an academic medical center), a registered nurse (RN), and a respiratory therapist (RT). Having an EMP as part of the COVID-19 airway team is logical because EMPs play an integral role during RSIs in the ED setting, serving as experts in medication selection and dosing. On the COVID-19 airway team at University of Iowa Hospitals and Clinics, the role and duties of an EMP can be categorized as follows:

-   Development---The EMP develops a medication kit that includes induction and neuromuscular blocking agents (NMBAs), sedatives, analgesics, and vasopressors ([Table 1](#T1){ref-type="table"}).

-   Facilitation---The EMP facilitates rapid delivery of medications to the bedside by responding to all endotracheal intubation calls with the COVID-19 airway team.

-   Evaluation---The EMP evaluates the patient's medical history and vital signs to make drug therapy recommendations, which include appropriate dosing for induction, administration of NMBAs, and postintubation sedation and analgesia.

-   Preparation---The EMP prepares recommended medications.

-   Support---The EMP provides recommendations for hemodynamic support before and after RSI and helps with the acquisition of needed medications from a satellite pharmacy if they are not stocked in the ED medication kit.

-   Documentation---The EMP documents all interventions and recommendations provided during and immediately after RSI.

###### 

COVID-19 Airway Team Medication Kit Contents

  Item                          Quantity
  ----------------------------- -------------------------------
  Medications                   
  Ketamine 10 mg/mL             1 x 20-mL vial
  Etomidate 2 mg/mL             2 x 10-mL vial
  Fentanyl 50 µg/mL             2 x 2-mL vial
  Midazolam 1 mg/mL             4 x 2-mL vial
  Propofol 500 mg/50 mL         1 x 50-mL vial
  Propofol 200 mg/20 mL         1 x 20-mL vial
  Phenylephrine 100 µg/mL       2 x 10-mL syringe
  Rocuronium 10 mg/mL           3 x 5-mL vial
  Succinylcholine 20 mg/mL^a^   1 x 10-mL vial
  Norepinephrine 1 mg/mL        1 x 4-mL vial
  Epinephrine 1 mg/mL           5 x 1-mL vial
  Sugammadex 100 mg/mL          4 x 5-mL vial
  Atropine 0.1 mg/mL            1 x 10-mL syringe
  Glycopyrrolate 0.2 mg/mL      2 x 1-mL vial
  Supplies                      
  Medication labels             1 roll
  20-mL syringe                 2
  10-mL syringe                 10
  3-mL syringe                  5
  18-gauge needle               10
  Filter needle                 10
  Alcohol swab                  10
  Gloves (medium)               10 pairs
  0.9% sodium chloride flush    10 x 5 mL
  0.9% sodium chloride bags     1 x 250-mL bag 1 x 100-mL bag

^a^Succinylcholine vial can be kept for 14 days at room temperature.

While having an EMP as part of the multidisciplinary COVID-19 airway team is a concept supported by most healthcare professionals, rapid implementation during the middle of an ongoing pandemic does not occur without challenges. The first challenge is providing 24/7 coverage. Most institutions (including ours) do not have the capability to provide 24/7 ED pharmacist coverage. To expand coverage quickly and efficiently, we had one of our critical care pharmacists and a postgraduate year 2 resident in emergency medicine pharmacy staff the open shifts. The second challenge is getting buy-in from all parties that may be impacted by EMP deployment outside the ED. It is important to have early and continual communication with the ED medical director and nursing leadership during protocol development so they are aware of the potential for the EMP to be temporarily reassigned outside the ED to help the COVID-19 airway team.

Participating as a team member on a COVID-19 airway team demonstrates the ability of EMPs to adapt to challenging situations and seek new opportunities to improve patient care during a pandemic. Future studies should evaluate the impact of EMP participation on a COVID-19 airway team on patient outcomes.

Disclosures: The authors have declared no potential conflicts of interest.
